Advertisement

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement

Jul

27

Today In Oncology

Does Bilateral Mastectomy for Unilateral Breast Cancer Impact Mortality

Patients With Prostate Cancer Social Factors May Be Tied to Racial Disparities in Cardiovascular Outcomes

Update on LEANer Trial in Patients With Breast Cancer

Triplet as Initial Salvage Treatment for Advanced Germ Cell Tumors Long-Term Outcomes

New Study Highlights Improvements in Treating Pediatric Patients With Retinoblastoma

Advertisement

© 2024 HSP News Service, L.L.C.